SAM #75F40126Q00327

Bundibugyo Virus (BDBV) Genome Sequencing and Analysis Services for 2026 Outbreak

This procurement opportunity is issued by the U.S. Food and Drug Administration (FDA), Office of Regulatory and Emerging Science (ORES), for sequencing and genomic analysis of Bundibugyo virus disease (BDBV) during the 2026 outbreak in the Democratic Republic of Congo and Uganda. - Government Buyer: - U.S. Food and Drug Administration (FDA), Office of Regulatory and Emerging Science (ORES) - Office of Acquisition and Grant Services (OAGS), Division of Acquisition Operations (DAO) - OEMs and Vendors: - University of Liverpool (contracted research institution) - Products/Services Requested: - Genome sequencing and analysis services for Bundibugyo virus (BDBV) from up to 1,000 patient samples - Includes generating high-quality full genome sequence data - Comparative analysis with previous outbreaks - Monitoring viral evolution - Data submission to NCBI GeneBank and FDA-ARGOS databases - Monthly and ad hoc reporting to FDA - Unique or Notable Requirements: - Strict compliance with information security and privacy standards - Deliverables include final reports and sequence data uploads - Firm fixed price contract - Focus on rapid, high-quality genomic data generation and analysis for outbreak response

Description

Title: Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak

Questions: 08/07/26

Responses Due: 08/10/26

View original listing